Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia

Children's Oncology Group

Status: Completed

Conditions: Leukemia

Treatments: Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Genetic: microarray analysis; Genetic: gene expression analysis; Genetic: DNA methylation analysis

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01229956

NCI-2011-02842 (Registry Identifier)

COG-AAML11B3 (Other Identifier)

AAML11B3 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of tissue from patients with cancer the in laboratory may help doctors identify and learn more about biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in tissue samples from young patients with acute myeloid leukemia.

Full description

OBJECTIVES:

• To determine whether the pattern of global and TSG-specific promoter CpG island hypermethylation and gene silencing that we have shown characterizes MLL-rearranged (MLL-r) infant bilineage ALL is also characteristic of other subsets of MLL-r leukemia.

OUTLINE: Previously collected cryopreserved cells from diagnosis are analyzed for promoter methylation via HELP arrays, gene expression arrays, and RT-qPCR.

PROJECTED ACCRUAL: A total of 32 samples (8 from each of 4 biologically defined cohorts) will be analyzed.

Enrollment: 32 estimated patients

Sex: All

Ages: 1 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Available cryopreserved cells from diagnosis

  • At least 2 x 10^7 viably cryopreserved cells

• One of the following biologically defined cytogenetics/molecular cohorts:

  • t(9;11)
  • t(11;19)
  • Other 11q23 translocations
  • Normal cytogenetics

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified